AI and Combination Therapies Highlighted at Alzheimer's Conference

The Stony Brook Center of Excellence for Alzheimer’s Disease is hosting a symposium on AI's transformative role in dementia care, focusing on early detection and therapeutic applications, including robotics. Concurrently, the medication Leqembi, covered by Original Medicare, poses significant costs for Alzheimer’s treatment, with patients potentially paying around $5,000 annually after deductibles. Recent discussions at the 2024 CTAD conference highlighted the potential of anti-amyloid antibodies like Leqembi and Kisunla as part of a new wave of Alzheimer’s therapies, emphasizing the importance of combination treatments for better outcomes. Experts suggest that while these drugs can slow disease progression by 30%, the goal is to achieve complete halting of Alzheimer’s. The global market for Alzheimer’s therapeutics is projected to reach $9.2 billion by 2030, reflecting increasing optimism in the field. Overall, innovation in both drug therapy and AI applications is shaping the future of Alzheimer’s care.